Stock Track | BioCryst Pharmaceuticals Soars 5.30% in Pre-Market on Strong Earnings Results and Revenue Beat

Stock Track

02/26

Biocryst Pharmaceuticals (BCRX) saw its stock price surge 5.30% in pre-market trading on Thursday, following the release of its fourth-quarter and full-year 2025 financial results.

The company reported quarterly adjusted earnings per share of $0.06, beating analyst estimates of $0.05 by 14.58%. Quarterly sales reached $163.284 million, exceeding consensus estimates of $151.326 million by 7.90% and representing a 24.14% increase over the same period last year.

For the full year 2025, BioCryst achieved a 94% increase in revenue, driven by strong U.S. sales of its ORLADEYO product. The company posted a non-GAAP operating profit of $214.2 million, a 198% year-over-year increase, and maintained its 2026 revenue guidance. Additional positive developments include FDA approval for ORLADEYO oral pellets for pediatric patients and the completion of the Astria Therapeutics acquisition, which expanded the company's hereditary angioedema (HAE) portfolio.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1198741282"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1198741282\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1198741282?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 21:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198741282","market":"nz","top_or_hot":-1,"title":"Stock Track | BioCryst Pharmaceuticals Soars 5.30% in Pre-Market on Strong Earnings Results and Revenue Beat","media":"Stock Track","content":"<p>Biocryst Pharmaceuticals (BCRX) saw its stock price surge 5.30% in pre-market trading on Thursday, following the release of its fourth-quarter and full-year 2025 financial results.</p><p>The company reported quarterly adjusted earnings per share of $0.06, beating analyst estimates of $0.05 by 14.58%. Quarterly sales reached $163.284 million, exceeding consensus estimates of $151.326 million by 7.90% and representing a 24.14% increase over the same period last year.</p><p>For the full year 2025, BioCryst achieved a 94% increase in revenue, driven by strong U.S. sales of its ORLADEYO product. The company posted a non-GAAP operating profit of $214.2 million, a 198% year-over-year increase, and maintained its 2026 revenue guidance. Additional positive developments include FDA approval for ORLADEYO oral pellets for pediatric patients and the completion of the Astria Therapeutics acquisition, which expanded the company's hereditary angioedema (HAE) portfolio.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BioCryst Pharmaceuticals Soars 5.30% in Pre-Market on Strong Earnings Results and Revenue Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BioCryst Pharmaceuticals Soars 5.30% in Pre-Market on Strong Earnings Results and Revenue Beat\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-02-26 21:07</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Biocryst Pharmaceuticals (BCRX) saw its stock price surge 5.30% in pre-market trading on Thursday, following the release of its fourth-quarter and full-year 2025 financial results.</p><p>The company reported quarterly adjusted earnings per share of $0.06, beating analyst estimates of $0.05 by 14.58%. Quarterly sales reached $163.284 million, exceeding consensus estimates of $151.326 million by 7.90% and representing a 24.14% increase over the same period last year.</p><p>For the full year 2025, BioCryst achieved a 94% increase in revenue, driven by strong U.S. sales of its ORLADEYO product. The company posted a non-GAAP operating profit of $214.2 million, a 198% year-over-year increase, and maintained its 2026 revenue guidance. Additional positive developments include FDA approval for ORLADEYO oral pellets for pediatric patients and the completion of the Astria Therapeutics acquisition, which expanded the company's hereditary angioedema (HAE) portfolio.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BCRX","symbol_name":"BioCryst製藥","start_time":0,"source_url":"","article_id":"1198741282","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198741282","pubTimestamp":1772111265,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Biocryst Pharmaceuticals (BCRX) saw its stock price surge 5.30% in pre-market trading on Thursday, following the release of its fourth-quarter and full-year 2025 financial results.The company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BCRX":"BioCryst制药"},"translate_title":"个股追踪|BioCryst Pharmaceuticals盘前大涨5.30%财报业绩强劲营收超预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCRX":1},"content_text":"Biocryst Pharmaceuticals (BCRX) saw its stock price surge 5.30% in pre-market trading on Thursday, following the release of its fourth-quarter and full-year 2025 financial results.The company reported quarterly adjusted earnings per share of $0.06, beating analyst estimates of $0.05 by 14.58%. Quarterly sales reached $163.284 million, exceeding consensus estimates of $151.326 million by 7.90% and representing a 24.14% increase over the same period last year.For the full year 2025, BioCryst achieved a 94% increase in revenue, driven by strong U.S. sales of its ORLADEYO product. The company posted a non-GAAP operating profit of $214.2 million, a 198% year-over-year increase, and maintained its 2026 revenue guidance. Additional positive developments include FDA approval for ORLADEYO oral pellets for pediatric patients and the completion of the Astria Therapeutics acquisition, which expanded the company's hereditary angioedema (HAE) portfolio.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}